Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Advanced Solid Tumors
Interventions: ARRY-382, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 30
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more

Conditions: Haematological Malignancies
Interventions: AS703569; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anemia, Sickle Cell
Interventions: Mindfulness-based Stress Reduction; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Smoking Cessation, Asthma
Interventions: Chart Reminders & New York State Quit line referral system; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Erdafitinib Intravesical Delivery System; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more

Conditions: Oral Health, Child, Adolescent, High-risk, Community Health Workers
Interventions: Treatment 1: Full GRIN course (Lessons 1-8), Treatment 2: Part 1 of GRIN (Lessons 1-4), Treatment 3: Part 2 of GRIN (Lesson 1, 5-8); Other
Lead sponsor: KDH Research & Communication; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 455 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizotypal Personality Disorder, SPD
Interventions: Cognitive Remediation Therapy, Guanfacine, Placebo; Behavioral · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematological Malignancies
Interventions: Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more

Conditions: Neoplasms, Advanced Solid Tumors
Interventions: JNJ-87890387; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Nashville, Tennessee

Conditions: Stress
Interventions: MB-Spirit, Strong Behaviors for Stress Reduction; Behavioral
Lead sponsor: Sara W Lazar; Other
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lumbar Stenosis
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 48 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Bereavement
Interventions: Vocal Expression, Cognitive Behavioral; Behavioral
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: HIV
Interventions: Monetary Incentive, Questionnaire Timing, HIV Test Offering; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 64 Years
Enrollment: 8,572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoma, Leukemia, Myeloma
Interventions: Resistance Training, Aerobic Exercise, Optional Aerobic Exercise Procedure, Optional In-Person Exercise Sessions; Behavioral · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depressive Disorder
Interventions: Depression Care Management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions: Ceritinib, Docetaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Pneumococcal Infections, Pneumococcal Vaccines
Interventions: V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 66
States / cities: Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801; Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 11
States / cities: La Jolla, California • Redlands, California • Whittier, California + 8 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Tofersen, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 17 more

Conditions: Ewing's Sarcoma
Interventions: Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more

Conditions: Neonatal Anemia
Interventions: Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III; Biological
Lead sponsor: John A Widness; Other
Eligibility: 1 Hour to 6 Months
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions: AOC 1001, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more

Search by objective public record fields.

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

MBSR for Pain Catastrophizing in SCD

Smoking Cessation Peds Asthma

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Guardians Receiving Information Through Navigators

CRT-Guanfacine for SPD

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of JNJ-87890387 for Advanced Solid Tumors

Assessing MB-Spirit for Psychological Well-being

The Prevalence of Directional Preference in the Lumbar Stenosis Population

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Bereavement Support Program for Caregivers

HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Depression Attention for Women Now (The DAWN Study)

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Red Blood Cell (RBC) Survival Following Transfusion in Infants

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients